Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
Abstract Objectives This study aimed to clinically validate the six‐gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cance...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.474 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576727216291840 |
|---|---|
| author | Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher |
| author_facet | Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher |
| author_sort | Agnieszka Krzyzanowska |
| collection | DOAJ |
| description | Abstract Objectives This study aimed to clinically validate the six‐gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T‐stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C‐indexes from Cox proportional hazard regression models. Results Biopsy MCRS was significantly prognostic (p < 0.0001) and added significant prognostic value to clinico‐pathological features for adverse pathology, high primary Gleason and high pathological T‐stage (p < 0.0001). MCRS was prognostic for biochemical recurrence and added some, albeit non‐significant, prognostic value to clinical risk stratifiers, which could reflect the low number of recurrence events in the cohort. Conclusion Biopsy‐based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer. |
| format | Article |
| id | doaj-art-f0067809c9c14348b7a0481287d2ea13 |
| institution | Kabale University |
| issn | 2688-4526 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-f0067809c9c14348b7a0481287d2ea132025-01-31T00:14:32ZengWileyBJUI Compass2688-45262025-01-0161n/an/a10.1002/bco2.474Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancerAgnieszka Krzyzanowska0Debra F. Higgins1Stephen Barron2Tony Loughman3Amanda O'Neill4Katherine M. Sheehan5Chan‐Ju Angel Wang6Bozena Fender7Leah McGuire8Joanna Fay9Anthony O'Grady10Des O'Leary11R. William Watson12Anders Bjartell13William M. Gallagher14Department of Translational Medicine, Division of Urological Cancers, Faculty of Medicine Lund University Lund SwedenOncoAssure Ltd, NovaUCD Dublin IrelandOncoAssure Ltd, NovaUCD Dublin IrelandOncoAssure Ltd, NovaUCD Dublin IrelandUCD School of Medicine, UCD Conway Institute of Biomolecular and Biomedical Research University College Dublin Dublin IrelandPathology, RCSI Education and Research Centre Beaumont Hospital Dublin IrelandOncoAssure Ltd, NovaUCD Dublin IrelandOncoAssure Ltd, NovaUCD Dublin IrelandOncoAssure Ltd, NovaUCD Dublin IrelandRCSI Biobank, RCSI Education and Research Centre Beaumont Hospital Dublin IrelandPathology, RCSI Education and Research Centre Beaumont Hospital Dublin IrelandOncoAssure Ltd, NovaUCD Dublin IrelandUCD School of Medicine, UCD Conway Institute of Biomolecular and Biomedical Research University College Dublin Dublin IrelandDepartment of Translational Medicine, Division of Urological Cancers, Faculty of Medicine Lund University Lund SwedenOncoAssure Ltd, NovaUCD Dublin IrelandAbstract Objectives This study aimed to clinically validate the six‐gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T‐stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C‐indexes from Cox proportional hazard regression models. Results Biopsy MCRS was significantly prognostic (p < 0.0001) and added significant prognostic value to clinico‐pathological features for adverse pathology, high primary Gleason and high pathological T‐stage (p < 0.0001). MCRS was prognostic for biochemical recurrence and added some, albeit non‐significant, prognostic value to clinical risk stratifiers, which could reflect the low number of recurrence events in the cohort. Conclusion Biopsy‐based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer.https://doi.org/10.1002/bco2.474gene expression signaturemolecular risk scorepatient managementprognosisprostate cancerrisk stratification |
| spellingShingle | Agnieszka Krzyzanowska Debra F. Higgins Stephen Barron Tony Loughman Amanda O'Neill Katherine M. Sheehan Chan‐Ju Angel Wang Bozena Fender Leah McGuire Joanna Fay Anthony O'Grady Des O'Leary R. William Watson Anders Bjartell William M. Gallagher Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer BJUI Compass gene expression signature molecular risk score patient management prognosis prostate cancer risk stratification |
| title | Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer |
| title_full | Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer |
| title_fullStr | Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer |
| title_full_unstemmed | Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer |
| title_short | Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer |
| title_sort | clinical validation of a biopsy based six gene signature prognostic for aggressive prostate cancer |
| topic | gene expression signature molecular risk score patient management prognosis prostate cancer risk stratification |
| url | https://doi.org/10.1002/bco2.474 |
| work_keys_str_mv | AT agnieszkakrzyzanowska clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT debrafhiggins clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT stephenbarron clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT tonyloughman clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT amandaoneill clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT katherinemsheehan clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT chanjuangelwang clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT bozenafender clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT leahmcguire clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT joannafay clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT anthonyogrady clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT desoleary clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT rwilliamwatson clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT andersbjartell clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer AT williammgallagher clinicalvalidationofabiopsybasedsixgenesignatureprognosticforaggressiveprostatecancer |